THE INFLUENCE OF ACID-SUPPRESSIVE THERAPY ON THE CLINICAL COURSE OF ISCHEMIC HEART DISEASE WITH REFRACTORY PAIN SYNDROME IN THE CHEST


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Frequent comorbid coronary heart disease (CHD) and gastroesophageal reflux disease (GERD) are defined by the presence of their common risk factors, relaxing the influence of a number of drugs for the treatment of coronary artery disease in the smooth muscles of the lower esophageal sphincter, as well as the ability to reflux during stimulation of the esophageal mucosa to cause reflex cardiac disorders including coronary artery spasm, and arrhythmia. Resistance chest pain to antianginal drugs may also be due to its non-coronary origin, including those associated with GERD. Appointment of proton pump inhibitors can not only restore the normal pH values of intraesophageal non-coronary arrest and chest pain caused by GERD, but also reduce the number and severity of episodes of pain associated with myocardial ischemia, which improves the clinical course of comorbid disease and improves the quality of life of patients. Rabeprazole (Pariet) has a number of positive characteristics that provide high speed of onset of effect, a weak dependence on the genetic polymorphism of liver enzymes, and minimal risk of drug-drug interactions, including drugs for the treatment of coronary artery disease, including clopidogrel.

Full Text

Restricted Access

About the authors

Georgy Leonidovich Yurenev

A.I. Evdokimov Moscow State Medical and Dental University

Email: yurenev@list.ru
MD; Professor of the Department of Propedeutics of Internal Medicine and Gastroenterology 127473, Moscow, 20/1 Delegatskaya st

Aleksandr Nisonovich Kazyulin

A.I. Evdokimov Moscow State Medical and Dental University

MD; Professor of the Department of Propedeutics of Internal Medicine and Gastroenterology 127473, Moscow, 20/1 Delegatskaya st

Tamara Vladimirovna Yureneva-Tkhorzhevskaya

A.I. Evdokimov Moscow State Medical and Dental University

PhD, Senior Researcher, Laboratory of Pulmonology 127473, Moscow, 20/1 Delegatskaya st

References

  1. Soran O. Treatment options for refractory angina pectoris: enhanced external counterpulsation therapy. Curr. Treat. Options Cardiovasc. Med. 2009;11:54-60.
  2. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006;101 (8):1900-20.
  3. Маев И.В., Юренев Г.Л., Бурков С.Г., Самсонов А.А., Задорова М.Г. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни. Тер. архив. 2007;3:57-66.
  4. Маев И.В., Трухманов А.С., Юренев Г.Л. Боли в грудной клетке при патологии пищевода. Сердце. 2007;6(6):300-4.
  5. Маев И.В., Юренев Г.Л. Некардиальные боли в грудной клетке: взгляд гастроэнтеролога и терапевта. КардиоСоматика. 2011;2:14-9.
  6. Лазебник Л.Б., Машарова А.А., Бордин Д.С., Васильев Ю.В., Ткаченко Е.М., Абдулхаков Р.А., Бутов М.А., Еремина Е.Ю., Зинчук Л.И., Цуканов В.В. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России (МЭГРЕ)»: первые итоги. Эксперимент. клин. гастроэнтерол. 2009;6:4-12.
  7. Беленков Ю.Н., Привалова Е.В., Юсупова А.О., Кожевникова М.В. Ишемическая болезнь сердца и рефлюкс-эзофагит: сложности дифференциального диагноза и лечения больных. Росс. журн. гастроэнтерол. гепатол. колопроктол. 2011 ;21 (3) :4-12
  8. Козлова И.В., Логинов С.В., Шварц Ю.Г. Гастроэзофагеальный рефлюкс и степень эзофагита у больных ишемической болезнью сердца: влияние на показатели реполяризации миокарда и вариабельность сердечного ритма. Клин. мед. 2004;9:33-5
  9. El-Serag H.B., Graham D.Y., Satia J.A., Rabenec L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol. 2005;100:1243-50.
  10. Wong W.M., Lai K.C., Lam K.F., Hui W.M., Hu W.H., Lam C.L., Xia H.H., Huang J.Q., Chan C.K., Lam S.K., Wong B.C. Prevalence, clinical spectrum and health care utilization of gastroesophageal reflux disease in a Chinese population: a population-based study. Aliment. Pharmacol. Ther. 2003;18(6):595-604.
  11. Chauhan A., Petch M.C., Schofield P.M. Cardio-esophageal reflex in humans as a mechanism for «linked angina». Eur. Heart J. 1996;17(3):407-13.
  12. Johansson S., Wallander M.A., Ruigomez A., Garda Rodriguez L.A. Is there any association between myocardial infarction, gastroesophageal reflux disease and acid suppressing drugs? Aliment. Pharmacol. Ther. 2003;18:973-8.
  13. Liuzzo J.P., Ambrose J.A. Chest pain from gastroesophageal reflux disease in patients with coronary artery disease. Cardiol. Rev. 2005;13:167-73.
  14. Bortolotti M., Labriola E., Bacchelli S., Degli Esposti D., Sarti P., Brunelli F., Del Campo L., Barbara L. "Oesophageal angina" in patients with angina pectoris: a possible side effect of chronic therapy with nitroderivates and Ca-antagonists. Ital. J. Gastroenterol. 1992;24(7):405-8.
  15. Nasseri-Moghaddam S., Nokhbeh-Zaeem H., Saniee P., Pedramnia S., Sotoudeh M., Malekzadeh R. Oral nitrate reductase activity and erosive gastro-esophageal reflux disease: a nitrate hypothesis for GERD pathogenesis. Dig. Dis. Sci. 2012;57:413-8.
  16. Nakaji G., Fujihara M., Fukata M., Yasuda S., Odashiro K., Maruyama T., Akashi K. Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey. Int. J. Clin. Pharmacol. Ther. 2011 ;49(9):555-62.
  17. Ruszniewski P., Soufflet C., Barthélémy P. Nonsteroidal antiinflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment. Pharmacol. Ther. 2008;28:1134-9.
  18. Маев И.В., Юренев Г.Л., Бурков С.Г., Вьючнова Е.С. Рабепразоловый тест и сравнительная оценка эффективности курсового лечения рабепразолом у больных гастроэзофагеальной рефлюксной болезнью с некоронарогенными болями в грудной клетке. Клин. мед. 2007;2:45-51.
  19. Юренев Г.Л. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни (клиника, диагностика, лечение, профилактика). Дисс.. докт. мед. наук. Москва, 2007:247 с.
  20. Fass R., Eslick G.D. Noncardiac chest pain: a growing medical problem. Plural Publishing Inc. San Diego, 2007:188 p.
  21. Liu Y., He S., Chen Y., Xu J., Tang C., Tang Y., Luo G. Acid reflux in patients with coronary artery disease and refractory chest pain. Intern. Med. 2013;52(11):1165-71.
  22. Budzynski J., Pulkowski G., Suppan K., Fabisiak J., Majer M., Ktopocka M., Galus-Pulkowska B., Wasielewski M. Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey. Health Qual. Life Outcomes. 2011 ; 9:77.
  23. Talwar V., Wurm P., Bankart M.J., Gershlick A.H., de Caestecker J.S. Clinical trial: chest pain caused by presumed gastrooesophageal reflux in coronary artery disease: controlled study of lansoprazole vs. placebo. Aliment. Pharmacol. Ther. 2010;32:191-9.
  24. Swiatkowski M., Budzynski J., Ktopocka M., Pulkowski G., Suppan K., Fabisiak J., Morawski W., Majer M. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit. 2004;10(9):CR524-9.
  25. Liuzzo J.P., Ambrose J.A., Diggs P. Proton pump inhibitors for patients with coronary artery disease associated with reduced chest pain, emergency department visits, and hospitalizations. Clinical cardiology. 2005;28(8):369-74.
  26. Liuzzo J., Ambrose J., Das S., Devoe M., Korabathina R., Agarwal S., Deshmukh S., Coppola J. Prospective, randomized, placebo-controlled evaluation of esomeprazole in coronary artery disease patients. EPAC: esomeprazole prevention of atypical chest pains. J. Invasive Cardiol. 2011 ;23(6):222-6.
  27. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009;157(1 ) :148.e1 -5.
  28. Маев И.В., Бурков С.Г., Юренев Г.Л. Гастроэзофагеальная рефлюксная болезнь и ассоциированная патология. М., 2014:352 с.
  29. Siriswangvat S., Sansanayudh N., Nathisuwan S., Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ. J. 2010;74(10):2187-92.
  30. Muñoz-Torrero J.F., Escudero D., Suárez C., Sanclemente C., Pascual M.T., Zamorano J., Trujillo-Santos J., Monreal M.; Factores de Riesgo y ENfermedad Arterial (FRENA) Investigators. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. J. Cardiovasc. Pharm. 2011 ;57(1 ):13-9.
  31. Venerito M., Kandulski A., Malfertheiner P. Dilemma zwischen Magenschutz und Kardioprotektion. Dtsch. Med. Wochenschr. 2010;135(44) :2193-8.
  32. Würtz M., Grove E.L., Kristensen S.D., Hvas A.M. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010;96(5):368-71.
  33. Huang K.W., Luo J.C., Leu H.B., Huang C.C., Hou M.C., Chen T.S., Lu C.L., Lin H.C., Lee F.Y., Chang F.Y. Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. J. Chin. Med. Assoc. 2013;76(1):9-14.
  34. Tsantes A.E., Ikonomidis I., Papadakis I., Bonovas S., Gialeraki A., Kottaridi C., Kyriakou E., Kokori S., Douramani P., Kopterides P., Karakitsos P., Lekakis J., Kapsimali V. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb. Res. 2013;132(2):e105-11.
  35. Moceri P., Doyen D., Cerboni P., Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb. Res. 2011 ; 128(5) :458-62.
  36. Hokimoto S., Mizobe M., Akasaka T., Arima Y., Kaikita K., Nakagawa K., Ogawa H. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation. Thromb. Res. 2014;133(4):599-605.
  37. Huang B., Huang Y., Li Y., Yao H., Jing X., Huang H., Li J. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch. Med. Res. 2012;43(3) :212-24.
  38. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. М.: Шико, 2011; в 2-х т
  39. Маев И.В., Юренев Г.Л., Бурков С.Г. Многоликая ГЭРБ: проблемы и решения. М.: ГЭОТАР-Медиа, 2015:386 с.
  40. Miner P., Delemos B., Xiang J., Lococo J., Ieni J. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. Aliment. Pharmacol. Ther. 2010;31 (9) :991 -1000.
  41. Васильев Ю.В. Ингибиторы протонного насоса. Леч. врач. 2007 ; 1:3-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies